Mithra obtains funding for up to EUR 100 million from existing investors and repurchases EUR 34.1 million of its convertible bonds due 2025 at a discount to par

Liege, Belgium, 8 August 2022 – 8:30 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to women’s health, announces today that it has entered into a senior secured convertible facilities agreement with funds managed by Highbridge Capital Management, LLC (collectively, “Highbridge”) and funds managed by Whitebox Advisors LLC (collectively, “Whitebox”, and together with Highbridge, each a “Lender”), for a three year term, in an amount of up to EUR 100 million. Part of the proceeds of the loan will be used to repurchase outstanding convertible bonds of the Company held by the Lenders for a principal amount of EUR 34.1 million at a discount.